AXSM
Axsome Therapeutics, Inc. NASDAQ Listed Nov 19, 2015$250.50
After hrs
$252.20
+0.68%
Mkt Cap $12.5B
52w Low $100.39
97.0% of range
52w High $255.17
50d MA $218.02
200d MA $168.12
P/E (TTM)
-68.1x
EV/EBITDA
—
P/B
141.1x
Debt/Equity
2.7x
ROE
-207.5%
P/FCF
-132.7x
RSI (14)
64.70
ATR (14)
$8.93
Beta
0.47
50d MA
$218.02
200d MA
$168.12
Avg Volume
667.8K
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
22 Cortlandt Street · New York City, NY 10007 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 4, 2026 | TNS | -0.85 | -1.26 | -48.2% | 223.70 | +1.1% | -0.3% | -0.2% | -1.1% | -1.3% | -0.4% | — |
| Feb 23, 2026 | TNS | -0.70 | -0.71 | -1.4% | 174.76 | +0.1% | -2.8% | -3.4% | -0.6% | +0.4% | +1.5% | — |
| Nov 3, 2025 | TNS | -0.82 | -0.94 | -14.6% | 135.75 | -1.3% | -0.6% | +0.6% | +2.7% | -0.9% | -0.3% | — |
| Aug 4, 2025 | TNS | -1.00 | -0.92 | +8.0% | 106.54 | -0.4% | -2.8% | -0.3% | +1.0% | +0.5% | -0.8% | — |
| May 5, 2025 | TNS | -1.26 | -0.80 | +36.5% | 116.49 | -0.6% | -3.7% | -1.2% | -1.8% | -1.0% | +2.2% | — |
| Feb 18, 2025 | TNS | -1.00 | -0.96 | +4.0% | 128.09 | +0.6% | -0.9% | +1.7% | +6.7% | -5.1% | -2.8% | — |
| Nov 12, 2024 | TNS | -1.38 | -1.34 | +2.9% | 99.49 | -0.5% | -1.7% | -0.5% | -4.3% | -0.8% | +3.3% | — |
| Aug 5, 2024 | TNS | -1.30 | -1.24 | +4.6% | 83.21 | +1.8% | +2.8% | -2.0% | +1.4% | -2.2% | +2.2% | — |
| May 6, 2024 | TNS | -1.20 | -1.09 | +9.2% | 75.94 | -0.5% | +1.3% | -1.6% | -2.6% | -1.6% | +4.3% | — |
| Feb 20, 2024 | TNS | -1.21 | -0.73 | +39.7% | 81.14 | -0.1% | +1.2% | -2.0% | -1.9% | +4.3% | +2.1% | — |
| Nov 6, 2023 | TNS | -1.24 | -1.32 | -6.5% | 62.42 | -1.1% | +1.1% | -2.5% | -2.4% | -4.4% | +3.3% | — |
| Aug 7, 2023 | TNS | -1.24 | -1.00 | +19.4% | 71.09 | +2.1% | +2.0% | -3.4% | +0.6% | -1.3% | +2.9% | — |
| May 8, 2023 | AMC | -1.13 | -0.22 | +80.5% | 77.73 | +0.0% | -1.3% | +4.5% | -2.8% | +1.3% | -1.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 1 | Needham | Maintains | Buy → Buy | — | $207.75 | $207.23 | -0.3% | -0.6% | +8.3% | -0.3% | -0.2% | -1.1% |
| Apr 10 | UBS | Maintains | Buy → Buy | — | $178.90 | $181.00 | +1.2% | -0.4% | +0.1% | +3.3% | +0.0% | +0.0% |
| Mar 25 | Guggenheim | Maintains | Buy → Buy | — | $158.75 | $160.74 | +1.3% | +1.9% | +1.5% | -4.8% | +2.7% | +5.3% |
| Feb 24 | Guggenheim | Maintains | Buy → Buy | — | $174.76 | $175.01 | +0.1% | -2.8% | -3.4% | -0.6% | +0.4% | +1.5% |
| Feb 24 | Wells Fargo | Maintains | Overweight → Overweight | — | $174.76 | $175.01 | +0.1% | -2.8% | -3.4% | -0.6% | +0.4% | +1.5% |
| Feb 24 | RBC Capital | Maintains | Outperform → Outperform | — | $174.76 | $175.01 | +0.1% | -2.8% | -3.4% | -0.6% | +0.4% | +1.5% |
| Feb 24 | UBS | Maintains | Buy → Buy | — | $174.76 | $175.01 | +0.1% | -2.8% | -3.4% | -0.6% | +0.4% | +1.5% |
| Feb 23 | Needham | Maintains | Buy → Buy | — | $183.72 | $176.42 | -4.0% | -4.9% | -2.8% | -3.4% | -0.6% | +0.4% |
| Feb 3 | Jefferies | Maintains | Buy → Buy | — | $185.88 | $188.25 | +1.3% | +0.8% | -1.0% | -2.5% | +0.9% | +0.4% |
| Jan 28 | Leerink Partners | Maintains | Outperform → Outperform | — | $188.02 | $187.69 | -0.2% | -1.5% | +0.1% | -0.6% | +0.9% | +0.8% |
| Jan 21 | RBC Capital | Maintains | Outperform → Outperform | — | $184.50 | $183.98 | -0.3% | +2.5% | -1.1% | -0.5% | -0.8% | +1.9% |
| Jan 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $177.27 | $178.00 | +0.4% | +4.1% | +2.5% | -1.1% | -0.5% | -0.8% |
| Jan 16 | Piper Sandler | Maintains | Overweight → Overweight | — | $174.14 | $175.71 | +0.9% | +1.8% | +4.1% | +2.5% | -1.1% | -0.5% |
| Jan 13 | Wells Fargo | Maintains | Overweight → Overweight | — | $176.82 | $177.91 | +0.6% | -1.4% | +1.5% | -1.6% | +1.8% | +4.1% |
| Jan 8 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $170.69 | $168.97 | -1.0% | -1.8% | +1.1% | +4.4% | -1.4% | +1.5% |
| Jan 6 | UBS | Maintains | Buy → Buy | — | $171.49 | $173.00 | +0.9% | +0.2% | -0.7% | -1.8% | +1.1% | +4.4% |
| Jan 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $178.69 | $178.88 | +0.1% | -4.0% | +0.2% | -0.7% | -1.8% | +1.1% |
| Dec 31 | Needham | Maintains | Buy → Buy | — | $148.79 | $158.49 | +6.5% | +22.8% | -2.2% | -4.0% | +0.2% | -0.7% |
| Nov 6 | Mizuho | Maintains | Outperform → Outperform | — | $135.69 | $135.66 | -0.0% | +2.7% | -0.9% | -0.3% | +1.3% | +0.9% |
| Nov 4 | Guggenheim | Maintains | Buy → Buy | — | $135.75 | $134.01 | -1.3% | -0.6% | +0.6% | +2.7% | -0.9% | -0.3% |
| Nov 4 | Morgan Stanley | Maintains | Overweight → Overweight | — | $135.75 | $134.01 | -1.3% | -0.6% | +0.6% | +2.7% | -0.9% | -0.3% |
| Nov 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $135.75 | $134.01 | -1.3% | -0.6% | +0.6% | +2.7% | -0.9% | -0.3% |
| Nov 4 | Wells Fargo | Maintains | Overweight → Overweight | — | $135.75 | $134.01 | -1.3% | -0.6% | +0.6% | +2.7% | -0.9% | -0.3% |
| Nov 4 | RBC Capital | Maintains | Outperform → Outperform | — | $135.75 | $134.01 | -1.3% | -0.6% | +0.6% | +2.7% | -0.9% | -0.3% |
| Nov 4 | Needham | Maintains | Buy → Buy | — | $135.75 | $134.01 | -1.3% | -0.6% | +0.6% | +2.7% | -0.9% | -0.3% |
| Oct 20 | Morgan Stanley | Maintains | Overweight → Overweight | — | $127.94 | $129.71 | +1.4% | +2.9% | -0.2% | -1.3% | -2.1% | +2.0% |
| Aug 6 | UBS | Maintains | Buy → Buy | — | $103.59 | $102.37 | -1.2% | -0.3% | +1.0% | +0.5% | -0.8% | +1.2% |
| Aug 5 | RBC Capital | Maintains | Outperform → Outperform | — | $106.54 | $106.12 | -0.4% | -2.8% | -0.3% | +1.0% | +0.5% | -0.8% |
| Aug 5 | BofA Securities | Maintains | Buy → Buy | — | $106.54 | $106.12 | -0.4% | -2.8% | -0.3% | +1.0% | +0.5% | -0.8% |
| Aug 4 | Needham | Maintains | Buy → Buy | — | $103.02 | $108.00 | +4.8% | +3.4% | -2.8% | -0.3% | +1.0% | +0.5% |
| Jun 12 | RBC Capital | Maintains | Outperform → Outperform | — | $108.08 | $107.32 | -0.7% | -1.7% | -2.0% | -2.3% | -0.1% | +1.3% |
| Jun 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $109.87 | $110.12 | +0.2% | +0.0% | -1.7% | -1.7% | -2.0% | -2.3% |
| Jun 9 | Needham | Maintains | Buy → Buy | — | $111.91 | $110.50 | -1.3% | -1.8% | +0.0% | -1.7% | -1.7% | -2.0% |
| May 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $105.76 | $105.16 | -0.6% | -1.3% | +0.7% | -1.0% | -1.0% | +1.6% |
| May 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $112.16 | $111.15 | -0.9% | -1.2% | -1.8% | -1.0% | +2.2% | -4.1% |
| May 6 | Wells Fargo | Maintains | Overweight → Overweight | — | $116.49 | $115.76 | -0.6% | -3.7% | -1.2% | -1.8% | -1.0% | +2.2% |
| May 6 | Baird | Maintains | Outperform → Outperform | — | $116.49 | $115.76 | -0.6% | -3.7% | -1.2% | -1.8% | -1.0% | +2.2% |
| Apr 29 | RBC Capital | Maintains | Outperform → Outperform | — | $107.24 | $107.62 | +0.4% | +2.5% | +2.2% | -0.0% | -0.0% | +3.8% |
| Apr 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $109.75 | $107.46 | -2.1% | -1.7% | -8.4% | -0.4% | -1.0% | +4.2% |
| Apr 1 | Needham | Maintains | Buy → Buy | — | $116.63 | $112.43 | -3.6% | -4.3% | -1.7% | -1.7% | -8.4% | -0.4% |
| Mar 27 | Mizuho | Maintains | Outperform → Outperform | — | $119.16 | $120.19 | +0.9% | +2.2% | -2.7% | -1.6% | -4.3% | -1.7% |
| Mar 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $125.10 | $123.51 | -1.3% | -0.6% | -1.8% | -2.8% | +0.6% | -0.0% |
| Mar 4 | RBC Capital | Maintains | Outperform → Outperform | — | $127.15 | $125.84 | -1.0% | -1.2% | -0.4% | -0.6% | -1.8% | -2.8% |
| Mar 3 | Needham | Maintains | Buy → Buy | — | $127.54 | $130.00 | +1.9% | -0.3% | -1.2% | -0.4% | -0.6% | -1.8% |
| Mar 3 | Baird | Maintains | Outperform → Outperform | — | $127.54 | $130.00 | +1.9% | -0.3% | -1.2% | -0.4% | -0.6% | -1.8% |
| Feb 27 | Morgan Stanley | Maintains | Overweight → Overweight | — | $128.33 | $129.53 | +0.9% | -1.5% | +0.9% | -0.3% | -1.2% | -0.4% |
| Feb 26 | Mizuho | Maintains | Outperform → Outperform | — | $127.09 | $128.09 | +0.8% | +1.0% | -1.5% | +0.9% | -0.3% | -1.2% |
| Feb 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $130.72 | $130.88 | +0.1% | -2.8% | +1.0% | -1.5% | +0.9% | -0.3% |
| Feb 24 | Needham | Maintains | Buy → Buy | — | $137.75 | $137.76 | +0.0% | -5.1% | -2.8% | +1.0% | -1.5% | +0.9% |
| Feb 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $126.96 | $128.13 | +0.9% | +1.7% | +6.7% | -5.1% | -2.8% | +1.0% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 11, 2026 | JEFFS ROGER | — | Sell | 286 | $249.12 | $71K | 58,367 | +0.55% | -0.66% |
| Jun 10, 2026 | JEFFS ROGER | — | Sell | 286 | $246.18 | $70K | 58,653 | +0.55% | -0.66% |
| Jun 10, 2026 | Coleman Mark | — | Sell | 643 | $249.00 | $160K | 30,389 | +3.02% | +0.10% |
| Jun 10, 2026 | Mahony Susan | — | Sell | 300 | $246.18 | $74K | 829 | +3.02% | +0.10% |
| Jun 9, 2026 | Mahony Susan | — | Sell | 300 | $237.21 | $71K | 1,129 | +3.02% | +0.10% |
| Jun 9, 2026 | Pizzie Nick | Chief Financial Officer | Sell | 33,000 | $240.09 | $7.9M | 42,867 | +0.28% | -0.59% |
| Jun 9, 2026 | TABUTEAU HERRIOT | Chief Executive Officer | Sell | 49,670 | $241.01 | $12.0M | 7,229 | +0.28% | -0.59% |
| Jun 2, 2026 | Coleman Mark | — | Sell | 5,537 | $223.39 | $1.2M | 29,603 | +5.10% | +4.47% |
| Jun 1, 2026 | Coleman Mark | — | Sell | 6,000 | $230.30 | $1.4M | 35,140 | +5.10% | +4.47% |
| May 29, 2026 | Coleman Mark | — | Sell | 6,000 | $233.46 | $1.4M | 41,140 | +5.10% | +4.47% |
| May 5, 2026 | Jacobson Mark L. | Chief Operating Officer | Sell | 233 | $228.18 | $53K | — | -0.19% | +3.49% |
| May 4, 2026 | Jacobson Mark L. | Chief Operating Officer | Sell | 4,517 | $227.94 | $1.0M | — | -0.19% | +3.49% |
8-K · 5.02
!!! Very High
Axsome Therapeutics, Inc. -- 8-K 5.02: Executive Change
Jun 9
8-K · 8.01
!! High
Axsome Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Jun 3
8-K · 2.02
!! High
Axsome Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Axsome Therapeutics reported quarterly earnings results, with financial details available in the attached press release for investor review of operational performance.
May 4
8-K · 8.01
!! High
Axsome Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
FDA approval of Axsome's AUVELITY for Alzheimer's dementia-related agitation expands the company's commercial opportunity in neurology and validates its therapeutic approach for this patient population.
Apr 30
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Axsome is acquiring TAK-063, an oral PDE10A inhibitor with potential in neuropsychiatric disorders, expanding its CNS pipeline and diversifying its portfolio beyond current offerings.
Apr 1
8-K
Axsome Therapeutics, Inc -- 8-K Filing
Axsome Therapeutics reported 2025 financial results and provided a business update, with the filing signed by CEO Herriot Tabuteau on February 23, 2026.
Feb 23
8-K · 8.01
!! High
Axsome Therapeutics, Inc -- 8-K 8.01: Material Event / Announcement
Axsome Therapeutics resolved patent litigation with Alkem regarding SUNOSI, eliminating a legal threat to the drug's market exclusivity in the United States.
Feb 17
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Portfolio Management Llc | 2,058,170 | $348M | New | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 1,937,752 | $328M | New | Mar 2026 |
| 3 | Fmr Llc | 1,566,995 | $265M | Added | Mar 2026 |
| 4 | Invesco Ltd. | 1,297,678 | $219M | Added | Mar 2026 |
| 5 | Morgan Stanley | 982,402 | $179M | Added | Dec 2025 |
| 6 | Assenagon Asset Management S.a. | 865,958 | $146M | Added | Mar 2026 |
| 7 | D.e. Shaw & Co | 603,465 | $102M | Added | Mar 2026 |
| 8 | Bank Of America Corp /de/ | 598,091 | $101M | Added | Mar 2026 |
| 9 | First Trust Advisors Lp | 577,479 | $98M | Added | Mar 2026 |
| 10 | Ubs Group Ag | 547,195 | $92M | Added | Mar 2026 |
| 11 | Pictet Asset Management Holding Sa | 436,063 | $80M | Added | Dec 2025 |
| 12 | Franklin Resources Inc | 438,490 | $74M | Added | Mar 2026 |
| 13 | Point72 Asset Management | 424,750 | $72M | Added | Mar 2026 |
| 14 | Northern Trust Corp | 401,459 | $68M | Added | Mar 2026 |
| 15 | Principal Financial Group Inc | 363,114 | $66M | Reduced | Dec 2025 |
| 16 | Hood River Capital Management Llc | 371,503 | $63M | Added | Mar 2026 |
| 17 | Nuveen, Llc | 335,737 | $57M | Reduced | Mar 2026 |
| 18 | Qube Research & Technologies Ltd | 335,334 | $57M | Added | Mar 2026 |
| 19 | Two Sigma Investments, Lp | 322,778 | $55M | Added | Mar 2026 |
| 20 | Citadel Advisors Llc | 281,503 | $48M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$12.46B
Enterprise Value
$12.28B
P/E (TTM)
-68.07x
Forward P/E
—
PEG Ratio
1.29x
P/B
141.13x
P/S
19.52x
P/FCF
-132.73x
EV/EBITDA
—
Shares Out
49.7M
Financials (TTM)
Revenue
$638.5M
Net Income
-$183.2M
EBITDA
-$168.1M
Free Cash Flow
-$93.9M
Op Cash Flow
-$93.4M
EPS Basic
$-3.68
EPS Diluted
$-3.68
EPS Forward
$-0.92
Gross Margin
92.6%
Op Margin
-26.5%
Net Margin
-28.7%
Balance Sheet
Total Assets
$689.8M
Total Liab.
$601.5M
Total Equity
$88.3M
Cash
$322.9M
LT Debt
$140.9M
Book Value/Sh
$1.77
Debt/Equity
2.73x
Current Ratio
1.55
Quick Ratio
1.48
Returns & Growth
ROE
-207.5%
ROA
-26.6%
ROIC
-44.0%
Rev Growth YoY
+65.5%
EPS Growth YoY
+38.6%
Price Returns
2W
+1.0%
1M
+12.9%
3M
+43.1%
6M
+54.8%
12M
+123.0%
Technicals
52W High
$255.17
52W Low
$100.39
50d MA
$218.02
200d MA
$168.12
RSI (14)
64.70
ATR (14)
$8.93
Beta
0.47
Avg Volume
668K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$223.71
High
$260.00
Low
$200.00
Median
$221.00
Data updated apr 24, 2026 8:15pm
· Source: financialmodelingprep.com